Kerri Fitzgerald

Articles by Kerri Fitzgerald

Kerri FitzgeraldMesothelioma | September 21, 2023
A phase I study presented at the American Association of Clinical Research Annual Meeting showed that chimeric antigen ...
Read More
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
The U.S. Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared ...
Kerri FitzgeraldLung Cancer | September 20, 2023
A study published in Thorax found that patients with chronic obstructive pulmonary disease (COPD) who have never smoked ...
Kerri FitzgeraldSmall Cell Lung Cancer | September 20, 2023
The U.S. Food and Drug Administration approved Imfinzi® (durvalumab) in combination with etoposide plus either ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
The U.S. Food and Drug Administration approved Tecentriq® (atezolizumab) in combination with Abraxane® (paclitaxel) ...
Kerri FitzgeraldLung Cancer | September 20, 2023
Air pollution is linked to nine specific causes of death, including lung cancer, according to a study published in JAMA ...
Kerri FitzgeraldLung Cancer | September 20, 2023
In the past decade, new lung cancer cases have decreased by 19% and five-year survival has increased by 26%, according ...
Kerri FitzgeraldLung Cancer | September 20, 2023
Men who are current or former smokers who have higher cardiorespiratory fitness may be less likely to develop lung ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
First-line Tagrisso® (osimertinib) improved overall survival (OS) compared with a comparator tyrosine kinase inhibitor ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to the oral MET inhibitor tepotinib ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
Pooled data from two clinical trials showed that nivolumab (Opdivo®) resulted in a fivefold increase in five-year ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
The experimental drug LOXO-292 (now called selpercatinib) shrank tumors in nearly 70% of lung tumors with the ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
A phase I/II study published in JAMA Oncology found that the HIV protease inhibitor Viracept® (nelfinavir mesylate) ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
A phase I/Ib study published in Clinical Cancer Research found that treatment with the immune checkpoint inhibitor ...
Kerri FitzgeraldSmall Cell Lung Cancer | September 19, 2023
The U.S. Food and Drug Administration (FDA) approved atezolizumab in combination with carboplatin and etoposide for ...
Kerri FitzgeraldLung Cancer | September 19, 2023
A study published in The Annals of Thoracic Surgery indicated that smoking cessation any time prior to surgery for ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 19, 2023
The U.S. Food and Drug Administration approved atezolizumab in combination with bevacizumab, carboplatin, and ...
Kerri FitzgeraldLung Cancer | September 19, 2023
U.S. lung cancer mortality is projected to decrease by 79% by 2065, according to a comparative model study ...